PHARMACOLOGY STUDY OF VPA 985 IN PTS W/ CHRONIC CONGESTIVE HEART FAILURE

VPA 985 在患有慢性充血性心力衰竭的 PTS 中的药理学研究

• 批准号: 6263616
• 负责人: ANDREW C KAO
• 金额: $ 2.51万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263616
• 关键词: azepines; clinical research; clinical trial phase I; congestive heart failure; diuresis; diuretics; drug adverse effect; drug screening /evaluation; heart pharmacology; human subject; liver cirrhosis; nephrotic syndrome; pharmacokinetics; phenylamide; vasopressins

This is a medical research study in which the patient is being asked to participate because they have congestive heart failure. Participation will assist in evaluating the safety and tolerance of multiple oral doses of VPA-985 in patients with chronic congestive heart failure CHF). In addition, another purpose is to assess how patients with CHF absorb and eliminate this drug. Lastly, information will be collected on some of the effects of this drug in patients with CHF. VPA-985 is an experimental drug. It is an aquaretic agent; this is, a drug that may promote an increased excretion of water by the kidneys. It is being developed for the possible treatment of patients with congestive heart failure (CHF), cirrhosis (liver disease), nephrotic syndrone (kidney disease) and syndrone of inappropriate antidiuretic hormone secretion (SIADH).

这是一项医学研究，患者被要求参与，因为他们患有充血性心力衰竭。参与将有助于评估多剂量口服VPA-985在慢性充血性心力衰竭(CHF)患者中的安全性和耐受性。此外，另一个目的是评估CHF患者如何吸收和消除这种药物。最后，将收集有关该药物对CHF患者的一些影响的信息。VPA-985是一种实验性药物。它是一种水乳剂；这是一种可能促进肾脏增加水分排泄的药物。它正在开发用于可能治疗充血性心力衰竭(CHF)、肝硬变(肝病)、肾病综合征(肾病)和抗利尿激素分泌不当综合征(SIADH)的患者。